


# ZebraSci Acquired by BD to Enhance Combination Product Testing Capabilities



Biologic products and therapies represent an increasingly large share of the overall biopharmaceutical market and many of those products are delivered parenterally. As injectable delivery methods and combination drug-device products continue to grow in importance, device manufacturers are seeking to expand their capabilities to include testing and validation of these combination products.

As one of the largest global medical technology companies in the world, BD is strengthening its leadership position by acquiring these testing and validation capabilities. ZebraSci, with its broad suite of manufacturing and testing

services for combination products in the injectables market, was the perfect acquisition target for BD. ZebraSci provides device technology selection, primary container engineering, device development, verification & validation, and stand-alone analytical and physical testing support.

Crosstree's deep sector expertise helped ZebraSci select BD as the ideal partner in a deal which will allow ZebraSci the opportunity to support BD's device manufacturing needs, continue to expand its service capabilities, and gain access to a broader range of potential customers.

**Crosstree helps clients develop and execute growth strategies that maximize synergies for all stakeholders.**

## ABOUT ZEBRASCI



ZebraSci provides pharmaceutical, biotechnology, and medical device companies with development, manufacturing and testing services, helping clients overcome their most difficult primary container and drug delivery device challenges.

With over 30,000 square feet of laboratory and manufacturing space between the company's East Coast and West Coast facilities, ZebraSci offers a broad suite of scientifically differentiated services ranging from device technology selection, primary container engineering, device development, verification & validation to stand-alone analytical and physical testing support.

## ABOUT BD



BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics.

## CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER — BY THE NUMBERS AND BEYOND — IS CROSSTREE'S SPECIALTY.

Crosstree's [proven track record](#) of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



**JASON LAYTON**

Director

[jason.layton@crosstreecapital.com](mailto:jason.layton@crosstreecapital.com)

813-578-7109